Genomind Revenue and Competitors

Location

$74M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Genomind's estimated annual revenue is currently $14.7M per year.(i)
  • Genomind's estimated revenue per employee is $155,000
  • Genomind's total funding is $74M.

Employee Data

  • Genomind has 95 Employees.(i)
  • Genomind grew their employee count by -9% last year.

Genomind's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Assistant Laboratory Director, VP Laboratory Regulation ComplianceReveal Email/Phone
3
Co founderReveal Email/Phone
4
VP Medical AffairsReveal Email/Phone
5
VP Global Business DevelopmentReveal Email/Phone
6
Area Director - CentralReveal Email/Phone
7
Senior Director FinanceReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
Customer Success ManagerReveal Email/Phone
10
Manager Project DeliveryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$258.5M866-19%$1.1B$2.4B
#2
$29.8M192-9%N/AN/A
Add Company

What Is Genomind?

Genomind is a personalized medicine company in neuropsychiatry. It was founded by a psychiatrist, Dr. Ronald Dozoretz, and a neurologist, Dr. Jay Lombard, who share a common goal of wanting the best possible care for patients who suffer from psychiatric illness. k

keywords:N/A

$74M

Total Funding

95

Number of Employees

$14.7M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Genomind News

2022-04-17 - Pharmacogenetic Testing in Psychiatry/Depression Market Is ...

BiogeniQ Inc., GenXys, Genomind, Inc., Myriad Genetics, Inc., AltheaDx, STADA Arzneimittel AG, Sonic Healthcare, ONEOME, Thermo Fisher...

2022-03-22 - Madison Core Laboratories Appoints New Chief Scientific Officer

... Health Network Laboratories in Allentown, PA; Vice President, Molecular Pathology and Laboratory Director, Genomind, King of Prussia,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.9M96N/AN/A
#2
$27.3M101-4%N/A
#3
$22.9M101-6%N/A
#4
$20.5M10259%N/A
#5
$14.8M102N/AN/A